No abstract available
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Breast Neoplasms / drug therapy
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Cell Differentiation
-
Cell Division
-
Cell Survival
-
Clinical Trials as Topic
-
Epidermal Growth Factor / antagonists & inhibitors
-
ErbB Receptors / antagonists & inhibitors*
-
Female
-
Gefitinib
-
Gene Expression Regulation, Neoplastic*
-
Head and Neck Neoplasms / drug therapy
-
Humans
-
Ligands
-
Lung Neoplasms / drug therapy
-
Ovarian Neoplasms
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Quinazolines / adverse effects
-
Quinazolines / pharmacology*
-
Survival
Substances
-
Antineoplastic Agents
-
Ligands
-
Quinazolines
-
Epidermal Growth Factor
-
ErbB Receptors
-
Protein-Tyrosine Kinases
-
Gefitinib